Sumanta Pal, MD
Enriched profileProfessor and Vice Chair of Academic Affairs, Department of Medical Oncology & Therapeutics Research (also Chair, Kidney and Bladder Cancer Disease Team; Co-Director, Kidney Cancer Program), City of Hope · City of Hope National Medical Center
Sumanta Pal is Professor and Vice Chair of Academic Affairs, Department of Medical Oncology & Therapeutics Research (also Chair, Kidney and Bladder Cancer Disease Team; Co-Director, Kidney Cancer Program), City of Hope at City of Hope National Medical Center. OpenAlex indexes 1,404 publications with 34,788 citations (h-index 89); ClinicalTrials.gov lists 17 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Sumanta Pal as a Highly Cited Researcher (Cross-Field, 2024).
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Sumanta Kumar Pal, MD, is Professor and Vice Chair of Academic Affairs, Department of Medical Oncology & Therapeutics Research (also Chair, Kidney and Bladder Cancer Disease Team at City of Hope National Medical Center / City of Hope Comprehensive Cancer Center, Duarte, CA. The public record shows 1,404 publications with 34,788 citations (h-index 89), centered on Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 19 companies.
- Most recent indexed publication: 2026 · Cancer research communications
- Top research focus: Renal cell carcinoma treatment
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 75 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 458.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Sponsor: City of Hope Medical Center
- Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
Sponsor: City of Hope Medical Center
Industry payments
Updated 15 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20254 payments
- Aveo Pharmaceuticals, Inc.Program year20253 payments
- Telix PharmaceuticalsProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.3%Kinase inhibitor44.6%Cabometyx64%Fotivda18%Everolimus10%Lenvima7%Part D<11 patientsGonadotropin Releasing Hormone Receptor Antagonist9.3%Orgovyx100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21%Proton pump inhibitor6.8%Pantoprazole Sodium100%Part D<11 patientsCorticosteroid6%Prednisone100%Part D≥13 patients+ 2 more classes in this area
Hormonal (systemic)
4.6%l-Thyroxine4.6%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors.
Cancer research communications
Article2026 - The seventh kidney cancer research summit: progress in accelerating cures.
The oncologist
Conference Proceedings2026 - From Sequencing to Treatment: Operational Challenges in Translating Precision Oncology Into Clinical Practice.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Review2026 - Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma.
Journal for immunotherapy of cancer
Article2026 - Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration.
JCO precision oncology
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/sumanta-pal-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/sumanta-pal-md-fasco-0927b74
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Google Scholar
scholar.google.com/citations
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗ - X / Twitter
x.com/montypal
Mentions by others
where others cite or feature them- Other
oncologytube.com/podcast-sumanta-pal-md-montypal-cityofhope-cityofhopeoc-asco22-oncotwitter-results-from-cohorts-3-4-5-of-the-cosmic-021-study
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncologytube.com ↗ - Other
akci.org/monty-pal
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →akci.org ↗ - Other
backtable.com/shows/urology/contributors/dr-sumanta-pal
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →backtable.com ↗ - Spotify
open.spotify.com/episode/10USVJq1pO1RsBS9jxpWsQ
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗ - X / Twitter
X/Twitter handle @montypal (Sumanta K. Pal, MD, FASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - LinkedIn
LinkedIn: Sumanta Pal, MD, FASCO - City of Hope
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →akci.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →akci.org ↗
- B.Sc./Bachelor's in Biology
California State University, Los Angeles, CONFLICTING DETAILS: AKCI bio states magna cum laude, 1998 …
1998provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →calstatela.edu ↗ - Board certified
Medical Oncology and Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Vice Chair of Academic Affairs
Department of Medical Oncology & Experimental Therapeutics, City of Hope
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Chair
Kidney and Bladder Cancer Disease Team, City of Hope
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Co-Director
Kidney Cancer Program, City of Hope
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →akci.org ↗ - Associate Editor
Genitourinary Cancers section, Cancer.Net (ASCO's patient information site)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.net ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Cross-Field2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →calstatela.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- President
Medical Oncology Association of Southern California (MOASC), term beginning 2026 -- MATERIAL UPDATE from prior 'Board of Directors' status, found via independent QA re-check
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Board of Directors
Medical Oncology Association of Southern California (MOASC) -- retained as historical/prior role, now superseded by Presidency above
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Media & interviews
press, podcasts and appearances- Guest
ASCO Daily News podcast episode "Key Takeaways From the 2025 ASCO Quality Care Symposium" (as 'Dr. Monty Pal')
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →open.spotify.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- Host
"On the Edge of Breakthrough: Voices of Cancer Research" podcast (City of Hope)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Guest
BackTable Urology Podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →backtable.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗
- Regular columnist/author for OncLive
CancerNetwork, and ACCC oncology media outlets
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Joanne Mortimer, MD
City of Hope National Medical Center
Vinod Pullarkat, MD
City of Hope National Medical Center
Tanya Dorff, MD
City of Hope National Medical Center
Alex Herrera, MD
City of Hope National Medical Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)